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Abstract  
Due to over-metabolism, the tumour cells become hypoxic. To overcome this situation tumour cells secret 
several chemical substrates to attract nearby blood vessels towards it (angiogenesis).  Transition from avascular 
to vascular tumour is possible with the initiation of angiogenesis. Angiogenesis also plays a crucial role to spread 
the cancer cells and its colonization at the distant locations of the body (metastasis). In this paper, we briefly 
review the processes and factors which directly affect tumour angiogenesis or may get affected by it. A model 
based on cellular automata is developed to demonstrate this complex process through MATLAB based 
simulation. 
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1. Introduction 
New blood vessels formation from the pre-existing blood vessels or by recruiting endothelial precursor cells 
(EPCs) from the bone marrow is known as neovascularization/angiogenesis. Neovascularization can be 
characterized into vasculogenic mimicry, and vessel co-option1,2. It is a fundamental process that can be seen in 
some of the physiological processes like reproduction, embryonic development, wound healing, and in some of 
the pathological processes like, vascularization of ischemic tissues3, rheumatoid arthritis4, diabetic retinopathy5, 
chronic inflammation, and tumour growth, its progression6 and metastasis7, etc. 
At the early stage, a tumour nodule does not have any direct vascular support; so it has to depend on the 
host’s vasculature for the nutrients, oxygen, and other growth elements. The metabolic demand of a tumour rises 
with its volume proportionally8, but it takes nutrients and oxygen proportionate to its surface area. As a result, 
cells near the tumour center become hypoxic due to the lack of oxygen and nutrients. At this situation, growth of 
the tumour would be stagnant (1-2 mm in diameter)9,10,11. Without direct access of the blood vessels, the hypoxic 
tumour cells gradually become necrotic. To continue its growth, the tumour shifts to an angiogenic phenotype 
and attracts surrounding blood vessels toward it.  
During angiogenesis, tumour cells secret a number of chemical species called tumour angiogenic factors 
(TAFs). These factors diffuse into the microenvironment through extracellular matrix (ECM) and damage the 
basement membrane of surrounding blood vessels. The TAFs disrupt the corresponding endothelial cell (EC) 
receptors which directly influence the structure of capillary networks. According to Sholley et al.12, without 
proliferation of ECs, capillary network cannot reach the tumour. Therefore, to complete vascularization 
successfully, ECs must undergo mutation phase. Finger like capillary sprouts are created from the disrupted 
areas of the surrounding blood vessels10. These capillary sprouts grow through the proliferation of recruited ECs 
from the parent vessels. The TAFs generate a chemical gradient (chemotaxis) between the tumour and the 
surrounding blood vessels; the capillary sprouts migrate toward the tumour. During angiogenesis, EPCs are 
brought into the walls of the growing capillary vessels through vascular channel from the bone marrow13 with 
the help of angiogenic factors14, though the percentage of EPCs are very low in general (Fig. 1). 
ECs of the capillary sprouts synthesize and secrete cellular fibronectin. This fibronectin does not diffuse in 
the microenvironment15 but increases the adhesiveness between the capillary sprouts and the ECM (haptotaxis)16. 
After covering certain distance towards the tumour, tube shaped capillary sprouts often are inclined toward each 
other and fuse together to form loops (anastomoses). These loops are the milestone of blood circulation within 
capillary network. From these loops new sprouts are generated and the same sequence of events are repeated to 
further extend the network. New capillary sprouts can also be generated from a sprout tip (branching). It has 
been seen that, as the capillary sprouts move toward the tumour, its branching ability rises till the tumour gets 
penetrated (vascularization). A vascular network is formed from the EC precursors (angioblasts) or from the dual 
hemopoietic/EC precursors (hemangioblats) in this way. This process is regulated by several pro–angiogenic 
factors such as, vascular endothelial growth factor (VEGF), acidic- and basic-fibroblast growth factor (a–, b–
FGF), placental growth factor (PLGF), angiopoietin–1, 2, and 4 (ANG–1, 2 and 4), etc.10 and some of the anti–
angiogenic factors like angiostatin, endostatin, thorombospondins (TSPs),  etc.17,18  
In physiological angiogenesis, pro- and anti- factors are in balance that regulates the growth of newly 
developed vessels, whereas, in tumour angiogenesis, the balance is disturbed and pro-factors become more 
powerful. As a result, newly developed vessels grow unboundedly and the vascular network becomes 
unorganized, often leaky, chaotic in nature, and haemorrhagic due to upregulation of growth factors. These 
vessels often carry tumour cells in their wall19. The blood flow within these networks is sometimes slow or 
sometimes oscillating that makes it dysfunctional20. Besides sprouting angiogenesis, researchers have identified 
other mechanisms of angiogenesis in tumours including intussusceptive angiogenesis, vasculogenic mimicry, 
and lymph–angiogenesis11, etc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Angiogenesis. 
 
 
In this paper, we review the crucial processes and factors which directly affect tumour angiogenesis 
(sprouting angiogenesis) or may get affected by it. Moreover, we study tumour angiogenesis from computational 
oncology perspective. In this context, initially we focus on hypoxia (formed during avascular phase) and its 
influence on angiogenesis. Mainly the roles of HIF–1α, HIF–2α for influencing TAFs are described. Attention 
has been paid on the roles of the pro- as well as anti- angiogenic factors like VEGF, FGF, PDGF, ANG, PLGF, 
TSPs, etc.  We also describe the influence of tumour angiogenesis in metastatic process and finally a simple 
cellular automata (CA) model based on a couple of assumptions/limitations has been described to explain 
sprouting angiogenesis. 
The paper is organized as follows: section 2 briefly describes the effects of hypoxia in angiogenesis; section 
3 illustrates the role of TAFs in angiogenesis which include pro- as well as anti- factors; section 4 illustrates the 
role of angiogenesis in metastatic process; section 5 describes the role of computational and mathematical 
models for tumour angiogenesis process through a simple CA based modelling; and section 6 concludes the 
paper. 
 
 
2. Roles of Hypoxia in Tumour Angiogenesis  
At the avascular stage, tumour cells require adequate blood supply; otherwise it gradually transforms into 
hypoxic due to high metabolic consumption and limited supply of oxygen and nutrients. At the hypoxic stage, 
local pH balance is disturbed, and oxygen and nutrients concentration in the surrounding microenvironment is 
sharply decreased21. The increasing distances between nearby vasculature and the tumour cells due to the tumour 
mass expansion are also responsible for the hypoxia. 
Hypoxia Inducible Factor–1 (HIF–1) is the main controller of the hypoxic response. It belongs to the basic 
Helix–Loop–Helix PER–ARNT–SIM (b–HLH–PAS) family which consists of αβ–heterodimers. HIF protein 
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family also includes HIF–1α, HIF–2α, HIF–3α, and HIF–1β. Activation of HIF directly affects tumour growth, 
as it is one of the crucial controllers of blood vessels development, maturation, and remodeling.  
Among the three α–subunits of the HIF family, only HIF–1α controls oxygen homeostasis in many cell 
types22, and it is a very influencing promoter for tumour growth as it controls EC activity (Fig. 2)23. The activity 
of HIF–1α is controlled by hydroxylation, acetylation, and phosphorylation24. It is responsible for transcription 
of lots of genes which are promoters in angiogenesis (including VEGF), cell proliferation, glucose and iron 
metabolism, etc.24 In hypoxic condition, the stability, subcellular localization, and transcriptional activity of 
HIF–1α are affected. The HIF–1α degradation is prohibited in hypoxia and its levels are accumulated to 
associate with HIF–1β to use transcriptional roles. In the post–translational modification of HIF–1α, enzymes 
prolyl–hydroxylase (PHD), and HIF prolyl–hydroxylase (HPH) play an important role and also help HIF–1α to 
associate with von Hippel–Lindau (VHL) tumour suppressor protein25. The activity of PHD depends on the 
oxygen levels which are also essential for transferring substrates to the proline residue of HIF–1α.  
Researchers have found a correlation between HIF–1α and HIF–2α with the activation of many pro–
angiogenic factors like VEGF, platelet–derived growth factor–B (PDGF–B), plasminogen activator inhibitor–1 
(PAI–1), the Tie–2 receptor, matrix metalloproteinases (MMP–2 and MMP–9), and angiopoiteins (ANG–1 and 
ANG–2)26. These influences destroy the balance between the pro– and anti–angiogenic factors27. Among these 
pro–angiogenic factors VEGF–A is highly expressed in most of the mammalian tumour in ECs28. In tumour, 
elevated VEGF are present at the boundary of necrotic and hypoxic cells. VEGF is responsible for the vessels 
formation and it has been discovered that HIF–1α acts as a primary regulator for VEGF. The other pro–
angiogenic proteins are also regulated by HIF for the vascular development during tumour angiogenesis. For 
example, HIF activates ANG–1 in ECs29, which help newly developed matured blood vessels during tumour 
angiogenesis by recruiting pericytes30. HIF–2α targets ANG–2 in ECs, whereas HIF–1α indirectly stimulates 
ANG–2 expression via VEGF29. On the other hand, ANG–1 and ANG–2 both influence Tie–2 receptor, which is 
a key player in vascular remodelling through destabilizing the existing vessels31. Scientists have also discovered 
that, loss of HIF–1α restricts angiogenesis in ECs including its proliferation and chemotactic migration23. Not 
only in tumour angiogenesis, scientists also got proof that HIF–1α, HIF–2α is also involved in metastasis of 
different cancers including brain, breast, colon, liver, lung, and etc.32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 HIF–induced angiogenic factors control angiogenic genes, angiogenic phases and functions during tumour 
angiogenesis (adapted from Krock et al.33) 
 
 
3. Angiogenetic Factors and Its Influences on Tumour Angiogenesis  
In 1968, it was first discovered that the tumour cells secret a number of chemical substrates34. In 1971, it was 
proposed that angiogenesis is an important phase for tumour growth and metastasis35. It is also found that 
prevention in angiogenesis may be a path to restrict the tumour growth. These possibilities motivated the search 
for angiogenic factors (pro– as well as anti–). Later, it is found that if pro– and anti– factors are in balance, then 
angiogenic switch (Fig. 3) is in off state and whenever the balance is lost it is in on state triggering angiogenesis 
in tumour7.  
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3.1 Pro–angiogenic Factors 
There are several factors like metabolic and mechanical stresses, immune response, genetic mutations, etc. which 
can trigger the angiogenic switch into on state36. The influences of environmental and genetic disorder on tumour 
angiogenesis and its growth are still unknown. Pro– factors like, VEGF, PLGF, FGF, ANG–1, ANG–2, PDGF, 
MMPs which are involved in tumour angiogenesis are described below (summarized in Table 1). We discuss 
about some anti-angiogenic factors in this context also.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 The angiogenic switch. 
 
 
VEGF/VEGFR 
VEGF, a pro–angiogenic factor, plays important roles in tumour angiogenesis. There are six members in the 
VEGF family which includes VEGF–A to E, and PLGF that communicate with tyrosine kinases, VEGFR–1, and 
VEGFR–2 to alter angiogenesis. Scientists have confirmed that the interplay between VEGF–A and VEGFR–2 
are the major contributors in sprouting angiogenesis11. VEGF–A is a highly specific mitogen for vascular ECs 
leading to the stimulation of the entire process required for neovascularization. So, it is also named as the 
vascular permeability factor (VPF). Members of VEGF family bind with tyrosine kinase receptors: VEGFRs, 
which is activated through trans-phosphorylation. In tumour angiogenesis, bindings between VEGF–A with 
VEGFR–2 is very crucial. The activities of VEGFR–1 are not well understood yet, though it is known to act as a 
dummy receptor to isolate VEGF from VEGFR–2 binding. VEGFR–2 is involved in almost all the known 
cellular responses to VEGF. PLGF is also a promoter of angiogenesis but its activities are less recognized. 
It is found that in tumours the level of VEGF is very high. Tumour cells secret VEGF to its surrounding 
environment. It is used for nourishment of the new blood vessels. At the primary phase of angiogenesis, vascular 
basement membrane is degraded by VEGF. Then, it binds with the receptors present on the EC surface and 
activates the proteins like, protein kinase B (PKB/Akt), phosphoinositide 3–kinase (PI–3K), and mitogen–
activated protein kinases (MAPK/ERK) which activate EC proliferation. VEGF also up-regulates plasminogen 
activators37, and MMPs38 during tumour angiogenesis. ECM degradation helps EC (of capillary sprouts) 
migration followed by the cell division to create tube shaped vessels. These newly developed vessels required 
stability or maturation. Angiopeotin family assures this stability and governs vascular growth. 
In the case of normal vessels, proper involvement of pericyte decreases EC proliferation and also reduces 
their dependence on the host tissue production of VEGF-A. On the contrary, improper association of pericyte 
may cause abnormal vessel diameter and sensitivity to VEGF inhibition, which may lead to apoptosis of ECs. 
Recent studies claim that ANG-1 and PLGF can provide survival signals and they have the ability to rescuing 
immature blood vessels from VEGF-A loss.  
 
FGF/FGFR 
FGFs are heparin binding factors. It binds with receptor tyrosine kinases (RTKs). FGFs and its receptors 
(FGFRs) control growth and differentiation of normal cells. FGF family consists of 23 members. Among them, 
a–FGF (acidic) (FGF–1), and b–FGF (basic) (FGF–2) are identified as the pro–angiogenic factors which 
influence EC proliferation and migration39. The up-regulation of FGF and FGFR are found in tumour cells. It is a 
very important factor for the angiogenesis cascade, though it does not have signaled sequences that trigger 
secretion. FGF is secreted in ECM; after that angiogenesis starts. In angiogenesis, FGF works with VEGF in co–
operated manner. So, the interaction between FGF and VEGF is also an important issue in tumour 
angiogenesis40.  
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The angiopoietin family consists of four members (identified till now), among which ANG–1, ANG–2, and 
ANG–4 are involved in angiogenesis. ANG–1, 2, and 4 bind with endothelial tyrosine kinase receptor: Tie–2. 
Angiopoietin family restricts several ligands to bind with the same receptors. While ANG–1 activates Tie–2 
signal, ANG–2 opposes its activation. The functions of ANG–1 are EC migration, adhesion, and pericyte 
recruitment; on the other hand ANG–2 destabilizes the vessels41. 
 
Table 1 Essential pro-angiogenic factors, their receptors, and functions  
 
Angiogenic Factors     Receptors         Functions 
VEGF      VEGFRs       
     (VEGFR–1,        
     VEGFR–2) 
initiation of angiogenesis 
1. permeability of vessels 
2. pericytes detachments 
3. basement membrane degradation 
neovascularization 
4. EC proliferation and migration 
5. pericyte proliferation and migration 
PLGF      VEGFR–1 neo–vessels formation  
1. proliferation and migration of ECs 
FGF      FGFRs neo–vessels formation  
1. proliferation and migration of ECs 
2. proliferation and migration of pericytes 
3. basement membrane degradation 
ANG–1      Tie–2 maturation 
1. accumulate EC and lumen 
2. pericytes attachment 
3. basement membrane deposition 
4. maintenance of vessels 
   ANG–2      Tie–2 initiation of angiogenesis 
1. pericytes detachments 
2. basement membrane degradation 
adaptation to tissue needs 
1. regression of neo vessels due to lack of flow or 
presence of growth factor  
PDGF–B      PDGFR neo–vessels formation  
1. proliferation and migration of ECs 
2. proliferation and migration of pericytes 
maturation 
1. pericytes attachment 
2. basement membrane deposition 
 
 
PDGF/PDGFR 
The PDGF family consists of five members: PDGF–A to D, and PDGF–AB. These proteins activate the 
downstream signals through binding PDGFR tyrosine kinases receptors and activating molecules like VEGF42,43. 
PDGFs are mainly involved in growth and progression of various kinds of cells. Scientists found a strong 
correlation between the up-regulation of PDGF, with FGF and VEGF44,45. PDGFs are involved in the recruitment 
of pericytes to the blood vessels, enhancement of secretion of other pro–angiogenic factors, endothelial 
proliferation and motility, sprouting and tube formation, promotion of lymph-angiogenesis, and subsequent 
lymphatic metastasis46.  
Besides the described factors, cancer cells produce other factors including transformation growth factor–β 
(TGF–β), epidermal growth factor (EGF), etc. TGF–β acts as a stabilizer of newly developed blood vessels and 
suppressor of the immune system47; and EGF up-regulates VEGF48. Other major factors for angiogenesis are 
MMPs. It helps to degrade the basement membrane of vessel’s wall and remodels ECM49. 
 
3.2 Anti–angiogenic Factors 
In tumour angiogenesis, pro-aniogenic factors are more up-regulated than anti-angiogenic factors. Anti-
angiogenic factors also exist in this mechanism to inhibit angiogenesis. Some of the anti-angiogenic factors are 
angiostatin, endostatin, thorombospondins (TSPs) etc.17,18 
 
Angiostatin 
It consists of one or more plasminogen fragments. This plasminogen is formed by proteolytic cleavage. 
Researchers showed that the combination of angiostatin and endostatin possess anti-tumour property against 
glioblastoma cells in vitro as well as in vivo and it increases proliferation, decreases micro-vessel density, 
enhances survival time of tumour and reduces tumour volume50.  
 
Endostatin 
It is a naturally developed anti-angiogenic factor from proteolytic cleavage (from XVIII collagen). It may 
communicate with multiple cell-surface molecules. Scientists have shown that the combination of endostatin 
with chemotherapy can enhance progression free survival and also improve clinical response in the case of 
advanced sarcomas patients51. 
 
TSPs 
TSPs are found to inhibit angiogenesis which delays tumour progression. Among the TSPs family TSP-1 is very 
important in tumour angiogenesis. Some studies have said TSP-1 has positive correlation with p53 in several 
types of tumours as p53 genes up-regulate TSP-1, down-regulate angiogenesis and suppress the tumour52,53. The 
roles of p53 in tumour angiogenesis are summarized in Table 2. 
 
Table 2 Roles of p53 genes in angiogenesis20 
 
                                  Factors up-regulated by p53 
TSP-1 Endogenous angiogenesis inhibitors 
MMP-2 Promotes endogenous anti-angiogenic peptide formation from 
basement-membrane proteins 
Brain specific angiogenesis 
inhibitors 
Brain specific endogenous angiogenesis inhibitors 
Eph receptor A2 (EphA2) EphA2 induces apoptosis; soluble EphA2 receptors are anti-angiogenic 
                                 Factors down-regulated by p53 
MMP-1 Promotes angiogenesis in bone and activates latent MMP-2 
VEGF-A Potent pro-angiogenic and permeability factor 
HIF–1α Induces angiogenesis by activation of VEGF-A transcription under 
hypoxic conditions 
Cyclooxygenase-2 Promotes angiogenesis 
 
 
 
4. Roles of Angiogenesis in Cancer Spread 
Angiogenesis is an essential phase for the tumour cell to metastasize. There is a very strong correlation among 
tumour micro vessels density (MVD), metastatic potential, and the poor survival rates54,55,56. In tumour 
angiogenesis, newly developed capillaries grow unboundedly. As a result, the vascular network becomes 
unorganized, often chaotic in nature, leaky and haemorrhagic due to up-regulation of growth factors. These 
vessels often carry tumour cells in their wall19. The leaky vessels enable hematogenous spread of cancer cells 
either singly or collectively57. After detaching from the primary tumour, cancer cells may enter into the leaky 
vessels and spread all-over the body to metastasize at remote sites.  
Due to angiogenesis, tumour gets direct access to the blood vessels, and absorbs oxygen and nutrients as 
much as possible for its unbounded proliferation. On the other hand, tumour secrets matrix degrading enzymes 
like, MMPs which help to remodel ECM49. Damaged ECM secrets a number of ECM-associated growth factors 
which also help tumour cells to grow faster and invade into the other tissues. As a result, tumour grows in 
volume and produces tremendous biomechanical pressure on the adjacent tissues including basement membrane, 
which gets dislocated and compressed. This phenomenon creates extra spaces for the tumour to grow and form 
″finger″ like protrusions of tumour cells that invade into the surrounding tissue along the minimum resistant path 
through ECM. The ability to invade surrounding tissues differentiates a malignant tumour from a benign tumour. 
Angiogenesis is not only providing nutrients and oxygen for the tumour cells but also it provides tumour cells 
a route to enter into the blood vessels or lymphatic vessels (intravasation). In intravasation, tumour cells detach 
from its neighbourhood and invade into the capillary vessels. It penetrates the basement membrane of vessels 
first and then damages EC barrier to enter into the blood stream with the help of transitional mesenchymal 
phenotype. These routes the tumour cells into the circulatory system. After invading into the blood and/or the 
lymphatic vessels, tumour cells collectively or singly spread to the other locations of the body through 
circulation in vessels. During the migration through the circulatory system, a lot of forces like, haemodynamic 
force, immunological stress, collisions with blood cells and ECs (of vessel wall) act on tumour cells together. 
Research showed that after 24 hours in circulation, less than 1 percent of cancerous cells are viable and less than 
0.1 percent survived to form metastasis58. The circulating tumour cells which succeed to survive from fluid shear 
and immune system of the body may get arrested to the vascular endothelium of secondary site and exit from the 
circulatory system to go into the tissue (extravasation). But, extravasation does not necessarily mean that the 
tumour cell is metastasizing. Singly migrated tumour cells that are extravasated mostly either apoptose, killed by 
immune system, or dormant59. After extravasation, tumour cell often make a colony of cells at the secondary site. 
This phenomenon is called metastasis. The secondary tumour also proliferates and undergoes angiogenesis to 
become fatal (macro-metastases). This metastatic tumour may re-metastasize to another site or can even re-
implant in the primary tumour60. Almost ninety percent patients suffering from cancer have died of metastasis.  
 
 
5. Tumour Angiogenesis: Computer Modelling Perspective 
Computational oncology involves computer-based modelling relating to tumour biology and cancer therapy. The 
aim is to build computer models that simulate biological processes and to use these models to make useful 
predictions. Scientists have developed various models to explain tumour growths as well as its progression from 
different perspectives as most of the processes involved in tumour growth are not clearly understood. A few 
computational and mathematical models of tumour angiogenesis are briefly discussed below. We also describe 
our own CA based discrete model for tumour angiogenesis.  
The work of Anderson and Chaplain61 is one of the most cited research paper in tumour angiogenesis 
modeling. In that study, they have presented both continuum as well as discrete models for capillary sprout 
formation in tumour angiogenesis. Both of these models consider the interactions between cell-ECM via 
fibronectin. They have concluded that chemotaxis as well as haptotaxis are the necessary factors for the 
development of capillary network and the chemotactic response should be strong enough for the initial 
outgrowth of capillary network. Milde et al.62 have developed a hybrid model of sprouting angiogenesis. The 
model combines continuum approximation of several TAFs, fibronectin, and EC density with discrete particle 
based sprout tip cells. The capillary vessels are represented by the continuous grid-independent particle mesh 
interpolation method. Also, filopodia are modeled explicitly to sense the migration and branching direction. The 
model explains that the structure and the density of the ECM has direct impact on the morphology, EC 
migration, expansion speed, the number of capillary branches, and network formation in the newly developed 
vessels.  
Wcisło et al.63 have developed a CA based 3-D multi-scale model based on particle dynamics for tumour 
angiogenesis. The tissue and fragments of vascular network are formed with particles and interact with the 
surrounding neighbors via mechanical resistance of the cell wall. The model was able to explain the realistic 3-
D dynamics of the entire tumour microenvironment consisting of normal and cancerous cells, blood vessels, and 
blood flow. Owen et al.64 have also developed a 3-D multi-scale model for tumour induced angiogenesis which 
includes vascular tissue growth with blood flow, capillary sprout formation, and vascular remodeling. The 
model has illustrated that the blood vessel pruning varies with the pressure drop across a vascular network 
proportionally. The model has explained the role of hypoxia in angiogenesis and also showed that the level of 
oxygen in blood controls the blood vessel generation. Shirinifard et al.65 have developed a 3-D cellular-pott 
model to mimic the solid tumour growth and angiogenesis by neglecting a few facts for example, anastomosis; 
possible presence of pericytes and ECM; dynamism among tumour cells; blood vessels attributes like, vessel 
diameter, blood flow rate, and vessel collapse due to external pressure; vessels remodeling etc. Lyu et al.66 have 
developed a hybrid model for tumour angiogenesis. The model has described the tumour growth process and the 
changes in the microenvironment from the avascular to the vascular stage. The study has well justified the 
physiological facts. 
In the next sub-section, CA based model for sprouting angiogenesis is proposed in 3-D framework by 
neglecting the dynamic nature of the tumour cells, dynamics of oxygen and nutrient concentrations, presence of 
pericytes, presence  of anti-angiogenic factors, differences between the veins and arteries, and smooth muscle 
cells.   
 
 
5.1 CA Model for Tumour Angiogenesis 
A CA model is proposed for tumour angiogenesis based on a couple of assumptions. The growth of a tumour 
becomes stagnant after it becomes 1-2 mm. in diameter9,10,11.  In our model, it is assumed that the tumour is a 
static entity by ignoring the changes in tumour cell dynamics. Once the tumour cells secret TAFs, it diffuse 
through the ECM and remodel the basement membrane of the nearby blood vessels. After stimulation by the 
TAFs, EC lining of the blood vessels form finger like sprouts which grow by recruiting the ECs of the parent 
vessels and move toward the tumour due to the higher concentration of TAFs. The capillary sprout tips (S) 
control the movement of these newly created capillaries. ECs secret fibronectin, creating adhesive force between 
the capillary sprouts and the ECM. On the other hand capillary sprouts secrete MMPs (upregulated by the 
TAFs), which remodel ECM. This also helps EC sprouts to make their way through the ECM.  
In our simulation, we consider that the tissue is represented by a 3-D grid of cells. The domain size of CA is 
[0, 1] X [0, 1] X [0, 1]. We assume that the spatial domain is discretized as x = ih, y = jh, z = kh (space step h), 
and the temporal domain t = n𝜏; where i, j, k, h, n, and 𝜏 are positive parameters. We consider that the spatial 
domain length is 2 mm. and the step size h = 0.01. Hence, a unit of step size represents 20 µm of dimensional 
length which is equivalent to the diameter of four ECs. 
We use Moore’s as well as von Neumann’s neighborhoods. M(Hi,j,k) refers to the Moore’s neighborhood 
elements of (i, j, k)th position in an arbitrary 3-D grid H, that is, Hi+1,j,k; Hi-1,j,k; Hi,j+1,k; Hi+1,j+1,k; Hi-1,j+1,k; Hi-1,j-1,k; 
Hi,j-1,k; Hi+1,j-1,k; Hi,j,k+1; Hi+1,j,k+1; Hi-1,j,k+1; Hi,j+1,k+1; Hi+1,j+1,k+1; Hi-1,j+1,k+1; Hi-1,j-1,k+1; Hi,j-1,k+1; Hi+1,j-1,k+1; Hi,j,k-1; 
Hi+1,j,k-1; Hi-1,j,k-1; Hi,j+1,k-1; Hi+1,j+1,k-1; Hi-1,j+1,k-1; Hi-1,j-1,k-1; Hi,j-1,k-1; Hi+1,j-1,k-1. Whereas N(Hi,j,k) refers to the von 
Neumann neighborhood of (i, j, k)th position in H, that is Hi+1,j,k; Hi-1,j,k; Hi,j+1,k; Hi,j-1,k; Hi,j,k+1; and Hi,j,k-1. In this 
model, we use several TAFs concentrations like VEGF (V), FGF (F), PDGF (P), ANG (A), etc., ECs (e), 
fibronectin (f), MMPs (m), and ECM (E). From the above considerations, the following CA rules (1-9) are 
formulated.  
 
𝑉𝑖,𝑗,𝑘
𝑛+1 = 𝑉𝑖,𝑗,𝑘
𝑛 + 𝜏 (𝛼1𝑎𝑣𝑔. (𝑀(𝑉𝑖,𝑗,𝑘
𝑛 )) − 𝛼2𝑉𝑖,𝑗,𝑘
𝑛 𝑎𝑣𝑔. (𝑒𝑖,𝑗,𝑘
𝑛 + 𝑀(𝑒𝑖,𝑗,𝑘
𝑛 )))                                          (1) 
𝐹𝑖,𝑗,𝑘
𝑛+1 = 𝐹𝑖,𝑗,𝑘
𝑛 + 𝜏 (𝛼3𝑎𝑣𝑔. (𝑀(𝐹𝑖,𝑗,𝑘
𝑛 )) − 𝛼4𝐹𝑖,𝑗,𝑘
𝑛 𝑎𝑣𝑔. (𝑒𝑖,𝑗,𝑘
𝑛 + 𝑀(𝑒𝑖,𝑗,𝑘
𝑛 )))                                          (2) 
𝑃𝑖,𝑗,𝑘
𝑛+1 = 𝑃𝑖,𝑗,𝑘
𝑛 + 𝜏 (𝛼5𝑎𝑣𝑔. (𝑀(𝑃𝑖,𝑗,𝑘
𝑛 )) − 𝛼6𝑃𝑖,𝑗,𝑘
𝑛 𝑎𝑣𝑔. (𝑒𝑖,𝑗,𝑘
𝑛 + 𝑀(𝑒𝑖,𝑗,𝑘
𝑛 )))                                          (3) 
𝐴𝑖,𝑗,𝑘
𝑛+1 = 𝐴𝑖,𝑗,𝑘
𝑛 + 𝜏 (𝛼7𝑎𝑣𝑔. (𝑀(𝐴𝑖,𝑗,𝑘
𝑛 )) − 𝛼8𝐴𝑖,𝑗,𝑘
𝑛 𝑎𝑣𝑔. (𝑒𝑖,𝑗,𝑘
𝑛 + 𝑀(𝑒𝑖,𝑗,𝑘
𝑛 )))                                         (4) 
𝑓𝑖,𝑗,𝑘
𝑛+1 = 𝑓𝑖,𝑗,𝑘
𝑛 + 𝜏(𝜔1𝑒𝑖,𝑗,𝑘
𝑛 − 𝜔2𝑓𝑖,𝑗,𝑘
𝑛 𝑒𝑖,𝑗,𝑘
𝑛 )                                                                                               (5) 
𝑚𝑖,𝑗,𝑘
𝑛+1 = 𝑚𝑖,𝑗,𝑘
𝑛 + 𝜏 (𝛾1𝑎𝑣𝑔. (𝑀(𝑚𝑖,𝑗,𝑘
𝑛 )) + 𝛾2𝜙(𝑖, 𝑗, 𝑘)𝑒𝑖,𝑗,𝑘
𝑛 − 𝛾3𝐸𝑖,𝑗,𝑘
𝑛 𝑚𝑖,𝑗,𝑘
𝑛 )                                        (6) 
 
           where 𝜙(𝑖, 𝑗, 𝑘) = {
1
0
                                                                                                                               (6.1) 
 
𝐸𝑖,𝑗,𝑘
𝑛+1 = 𝐸𝑖,𝑗,𝑘
𝑛 − 𝜏 𝜆𝑎𝑣𝑔. (𝑀(𝑚𝑖,𝑗,𝑘
𝑛 )) 𝐸𝑖,𝑗,𝑘
𝑛                                                                                               (7) 
          𝐷𝑖𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝑜𝑓(𝑆𝑖,𝑗,𝑘
𝑛+1) = 𝑖𝑛𝑑𝑒𝑥 𝑜𝑓 𝑚𝑎𝑥(𝜓𝑖,𝑗,𝑘
𝑛 , 𝜓𝑖+1,𝑗,𝑘
𝑛 , 𝜓𝑖−1,𝑗,𝑘
𝑛 , 𝜓𝑖,𝑗+1,𝑘
𝑛 , 𝜓𝑖,𝑗−1,𝑘
𝑛 , 𝜓𝑖,𝑗,𝑘+1
𝑛 , 𝜓𝑖,𝑗,𝑘−1
𝑛 )      (8) 
            
            where 𝜓𝑖,𝑗,𝑘
𝑛 = (𝜇1𝑉𝑖,𝑗,𝑘
𝑛 +𝜇2𝐹𝑖,𝑗,𝑘
𝑛 +𝜇3𝑃𝑖,𝑗,𝑘
𝑛 + 𝜇4𝐴𝑖,𝑗,𝑘
𝑛 ) + 𝑤2𝑒𝑖,𝑗,𝑘
𝑛 𝑓𝑖,𝑗,𝑘
𝑛 + 𝑤3𝑝𝑖,𝑗,𝑘
𝑛 𝑑𝑖,𝑗,𝑘                          (8.1)  
         
           
           𝑒𝑖,𝑗,𝑘
𝑛+1 = 𝑒𝑖,𝑗,𝑘
𝑛 + 𝜏 (𝛽 (𝜒(𝑖, 𝑗, 𝑘) × 𝑎𝑣𝑔. (𝑁(𝑒𝑖,𝑗,𝑘
𝑛 ))) (𝜇1𝑉𝑖,𝑗,𝑘
𝑛 +𝜇2𝐹𝑖,𝑗,𝑘
𝑛 +𝜇3𝑃𝑖,𝑗,𝑘
𝑛 + 𝜇4𝐴𝑖,𝑗,𝑘
𝑛 ))                (9) 
     
            where 𝜒(𝑖, 𝑗, 𝑘) = {
1
0
                                                                                                                               (9.1) 
 
In these Equations (1 – 9), α1 through α8, ω1, ω2, γ1 through γ3, λ, w1 through w3, µ1 through µ4, and β are the 
positive parameters having values between 0 and 1. 𝑎𝑣𝑔. (𝑀(𝑉𝑖,𝑗,𝑘
𝑛 )) represents the average value of Moore’s 
neighborhood of VEGF concentration, and 𝑎𝑣𝑔. (𝑁(𝑒𝑖,𝑗,𝑘
𝑛 )) symbolizes the average value of von Neumann’s 
neighborhood of EC concentration at the time instance n. In the Equation (8.1), 𝑝𝑖,𝑗,𝑘
𝑛
 is the randomly generated 
value between 0 to 1 at the time instance n, and di,j,k is the reciprocal of the distance between the tumour center 
and the point (i, j, k). If Equation (8) returns the position (i, j, k), then it indicates that the sprout tip will be in the 
idle position otherwise the sprout moves to a neighboring specified position if and only if the position is not pre-
occupied.  
The rule of anastomosis and branching is not clearly known. So, for this simulation, we consider that 
anastomosis occurs if and only if two sprout tips are situated at the adjacent positions (von Neumann neighbour) 
of the grid and Pa is the chances of anastomoses. On the other hand, conditions for branching are as follows,  
i) The sprout tip should be mature (age ≥ ageth). 
ii) There should be sufficient space available for branching. 
iii) The probability for branching of a sprout tip is Pb. 
Capillary sprout branching can happen if and only if these three conditions are true simultaneously. 
If any von Neumann neighbor of (i, j, k) belong to an EC at n  
Otherwise. 
 
If (i, j, k) represents a sprout tip at the time instance n. 
Otherwise. 
chemotaxis haptotaxis random motility 
 5.2 Parameters Estimation and Simulation 
In this simulation, each and every component is initialized with the proper values. For example, 
𝑉(𝑥, 𝑦, 𝑧, 0) = 𝜎1𝑒
−(1−𝑦)2
𝜀1 , (𝑥, 𝑦, 𝑧) ∈ [0,1] × [0,1] × [0,1] 
𝐹(𝑥, 𝑦, 𝑧, 0) = 𝜎2𝑒
−(1−𝑦)2
𝜀2 , (𝑥, 𝑦, 𝑧) ∈ [0,1] × [0,1] × [0,1] 
𝑃(𝑥, 𝑦, 𝑧, 0) = 𝜎3𝑒
−(1−𝑦)2
𝜀3 , (𝑥, 𝑦, 𝑧) ∈ [0,1] × [0,1] × [0,1]                                     (10) 
𝐴(𝑥, 𝑦, 𝑧, 0) = 𝜎4𝑒
−(1−𝑦)2
𝜀4 , (𝑥, 𝑦, 𝑧) ∈ [0,1] × [0,1] × [0,1] 
                                      and 𝑓(𝑥, 𝑦, 𝑧, 0) = 𝜎5𝑒
−𝑦2
𝜀5 , (𝑥, 𝑦, 𝑧) ∈ [0,1] × [0,1] × [0,1] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Flow chart of CA based simulation for tumour angiogenesis. 
N 
Y 
Vessels Branching 
Update tip cells (migration and maturation of tip cell) 
Anastomosis 
Initialization of grid size 
Initialize VEGF (V), FGF (F), PLGF (P), Ang (A), fibronectin (f), ECM (E), EC (e), 
MMPs (m), sprout tip cells (s), and other parameters like, α1 to α8, ω1, ω2, γ1 to γ3, 𝜆, 
w1, to w3, µ1 to µ4 and β. Also initialize Pa, Pb, and ageth. Also, initialize i = 1. 
Update VEGF (V), FGF (F), PLGF (P), ANG (A), fibronectin 
(f), ECM (E), EC (e), MMPs (m) 
  START 
     If i ≤ FULL? 
Graphical output 
  STOP 
i = i + 1 
where σ1 = 1.0, σ2 = 0.95, σ3 = 0.90, σ4 = 0.85, σ5 = 1.0, ε1 = 0.45, ε2 = 0.40, ε3 = 0.35, ε4 = 0.30, and ε5 = 0.45. 
The ECM is initialized with random values between 0 and 1. We assume that, the tumor centre is located at (0.5, 
0, 0.5) and the radius of the tumour is 1 mm or 50h. The pre-existing blood vessels are represented by the 
horizontal straight lines (0, 0, 0.2) to (1, 0, 0.2); (0, 0, 0.4) to (1, 0, 0.4); (0, 0, 0.6) to (1, 0, 0.6); (0, 0, 0.8) to (1, 
0, 0.8); and the vertical straight lines (0.3, 0, 0) to (0.3, 0, 1) and (0.6, 0, 0) to (0.6, 0, 1), respectively. The new 
capillary sprouts can be generated randomly from any point on these blood vessels. We also consider that 
initially MMPs are not present in the spatial domain, but the tip cell of capillary sprouts secrets MMPs, hence, at 
t = 0 MMPs is initialized with 0. 
The level of concentrations of all the substrates mentioned above are non-dimensional and scaled between 0 
and 1. In the updation rules definined by the Equations (1 – 9), the parameter values used for simulations are α1 
= 0.001, α2 = 0.1, α3 = 0.001, α4 = 0.09, α5 = 0.001, α6 = 0.08, α7 = 0.001, α8 = 0.075, ω1 = 0.05, ω2 = 0.1, 𝛾1 = 
0.01, 𝛾2 = 0.009, 𝛾3 = 0.0075, 𝜆 = 0.1, β = 0.1, and 𝜏 = 1 (equivalent to 2.4 Hrs.). We consider that a sprout 
maturation time (ageth) is 10𝜏 (equivalent to 24 Hrs.).  
All the grid elements are updated concurrently. At each time step, we update the values of VEGF, FGF, 
PDGF, ANG concentrations, ECs density, fibronectin, MMPs, capillary sprout tips, and the ECM. The 
algorithm (Fig. 4) is executed with w1 = 0.30, w2 = 0.40, and w3 = 0.30 to observe the effects of chemotaxis, 
haptotaxis, and random motility on the sprout tip-cell movement on 5th, 10th, 15th, and 20th day (Fig. 5 (a)-(d)) 
respectively.  
Through the  simulation described above, a number of observations are made:  a) no two capillary sprouts are 
generated from adjacent locations; b) as the sprouts approach closer to the tumour, its branching tendency 
increases, c) chemotaxis is the most effective driving force than haptotaxis as there is no significant changes 
visible with w2 = 0. 
 
 
 
  
(a)                                                                                     (b) 
   
(c)                                                                                 (d)      
Fig. 5 Capillary sprout formation in tumour induced angiogenesis due to chemotaxis, haptotaxis, and random 
motility on (a) 5th, (b) 10th, (c) 15th, and (d) 20th day respectively. 
 
6. Conclusions  
Angiogenesis is a critical phase in cancer as it acts as a bridge between avascular and vascular stage. To 
overcome the hypoxic state, tumour cells switch into angiogenic phenotype to attract nearby blood vessels. It is 
regulated by pro- and anti- factors. Tumour angiogenesis also acts as a medium for metastatic spread of cancer 
cells at the distant locations. It was hypothesized that if somehow angiogenesis would get inhibited then the 
aggressiveness and the progression of a tumour would be reduced. This was the motivation for active research on 
tumor angiogenesis. Unfortunately, very less information is available regarding the processes involved in tumour 
angiogenesis.  
To overcome this situation, computer-based modelling can be used. The aim is to build a computer model that 
simulates tumour angiogenesis to make useful predictions. In order to achieve this objective, a CA based simple 
model is proposed to demonstrate this phenomenon. Using the interactions in 3-D tissue space, we study the 
effects of various biological factors like, VEGF, FGF, PDGF, ANG, MMPs, fibronectin, and ECM on the 
capillary sprouts formation. The model also captures anastomoses and branching phenomena in capillary blood 
vessels. In each run of the simulation, the number of sprout formation and locations are varied randomly. 
Overall, the model justifies the practical scenario though it needs to be examined further with more factors and 
more details by including dynamic nature of the tumour cells, dynamics of oxygen and nutrient concentrations, 
capillary vessels pruning, and blood flow through the newly formed vessels. 
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